The East Tennessee Alzheimer’s Clinic is actively engaged in clinical trials for Alzheimer’s treatment, which play a vital role in the development of new treatment methods. These trials aim to evaluate the safety and efficacy of new drugs or treatment strategies.
Currently, there are several clinical trials related to Alzheimer’s disease in Tennessee. For example, the BENFO TEAM trial (NCT06223360) is assessing the safety, effectiveness, and tolerability of benfotiamine in patients with early – stage Alzheimer’s disease. The ADEPT – 1 trial (NCT05511363) is a phase 3 study focusing on the treatment of psychosis associated with Alzheimer’s disease using karxt. Additionally, the Generation Program is recruiting people aged 60 – 75 who may be at high risk of developing Alzheimer’s disease due to age, family history, or genetic background, to participate in related research.
These clinical trials provide hope for the development of more effective treatments for Alzheimer’s disease, and also offer opportunities for patients to access new treatment methods at an early stage.
Related topics:
